Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer
journal contribution
posted on 2018-05-15, 00:00 authored by R Shakya, GA Tarulli, L Sheng, NA Lokman, C Ricciardelli, KI Pishas, CI Selinger, MRJ Kohonen-Corish, WA Cooper, AG TurnerMissense mutations in the TP53 tumor-suppressor gene inactivate its antitumorigenic properties and endow the incipient cells with newly acquired oncogenic properties that drive invasion and metastasis. Although the oncogenic effect of mutant p53 transcriptome has been widely acknowledged, the global influence of mutant p53 on cancer cell proteome remains to be fully elucidated. Here, we show that mutant p53 drives the release of invasive extracellular factors (the 'secretome') that facilitates the invasion of lung cancer cell lines. Proteomic characterization of the secretome from mutant p53-inducible H1299 human non-small cell lung cancer cell line discovered that the mutant p53 drives its oncogenic pathways through modulating the gene expression of numerous targets that are subsequently secreted from the cells. Of these genes, alpha-1 antitrypsin (A1AT) was identified as a critical effector of mutant p53 that drives invasion in vitro and in vivo, together with induction of epithelial-mesenchymal transition markers expression. Mutant p53 upregulated A1AT transcriptionally through the involvement with its family member p63. Conditioned medium containing secreted A1AT enhanced cell invasion, while an A1AT-blocking antibody attenuated the mutant p53-driven migration and invasion. Importantly, high A1AT expression correlated with increased tumor stage, elevated p53 staining and shorter overall survival in lung adenocarcinoma patients. Collectively, these findings suggest that A1AT is an indispensable target of mutant p53 with prognostic and therapeutic potential in mutant p53-expressing tumors. © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Funding
Category 1 - Australian Competitive Grants (this includes ARC, NHMRC)
History
Volume
36Issue
31Start Page
4469End Page
4480Number of Pages
12eISSN
1476-5594ISSN
0950-9232Publisher
Nature Publishing Group, UKPublisher DOI
Full Text URL
Peer Reviewed
- Yes
Open Access
- No
Acceptance Date
2017-02-05External Author Affiliations
UNSW Australia; Garvan Institute of Medical Research, Sydney; University of Sydney; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital;University of Western Sydney; The University of AdelaideEra Eligible
- Yes
Journal
OncogeneUsage metrics
Categories
Licence
Exports
RefWorksRefWorks
BibTeXBibTeX
Ref. managerRef. manager
EndnoteEndnote
DataCiteDataCite
NLMNLM
DCDC